SCHEDULE: FMR LLC Boosts Zenas Biopharma Stake to 14.3%

FMR LLC and Abigail P. Johnson have disclosed a 14.3% beneficial ownership stake in Zenas Biopharma Inc. common stock as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 7,652,255 shares of Zenas Biopharma Inc. common stock.
• This represents 14.3% of the total outstanding common stock of Zenas Biopharma Inc.
• FMR LLC, a Delaware-organized parent holding company, holds sole voting power over 7,651,279 shares and sole dispositive power over 7,652,255 shares.
• Abigail P. Johnson, a U.S. citizen, holds sole dispositive power over 7,652,255 shares, with no sole voting power directly.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• FMR LLC's subsidiaries, including Fidelity Management & Research Company LLC, are identified as entities beneficially owning shares, with Fidelity Management & Research Company LLC owning 5% or greater.
• The Johnson family, including Abigail P. Johnson, are the predominant owners of FMR LLC's Series B voting common shares, forming a controlling group with respect to FMR LLC.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. A significant stake by a reputable institutional investor like FMR LLC can be interpreted as a strong endorsement of Zenas Biopharma's value proposition and future potential, though the filing itself is purely factual.

Positives

• Significant institutional investment from FMR LLC, a major financial services firm, indicates confidence in Zenas Biopharma Inc.
• The acquisition of shares was made in the ordinary course of business, suggesting a long-term investment strategy rather than an activist stake.

Risks

• No specific risks related to Zenas Biopharma Inc.'s operations or financial health are disclosed in this ownership filing.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding Zenas Biopharma Inc.'s future operations or financial performance. It is solely an ownership disclosure.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that large institutional holdings, such as the 14.3% stake by FMR LLC in Zenas Biopharma, are common in the biopharmaceutical sector. These investments often reflect a long-term view on the potential of a company's drug pipeline or market position. Such a significant stake from a prominent asset manager like FMR LLC can signal a vote of confidence in Zenas Biopharma's strategic direction and future prospects, potentially attracting further investor interest.

Comparison to Industry Standards

• Institutional ownership levels vary widely across the biopharma industry. For example, companies like Amgen (AMGN) and Gilead Sciences (GILD) typically see aggregate institutional ownership well over 80-90%.
• A 14.3% stake by a single major institutional investor like FMR LLC in Zenas Biopharma is a substantial position, indicating a strong conviction.
• While not as high as the aggregate institutional ownership in larger, more mature biopharma firms, it represents a significant individual commitment, comparable to leading positions taken by large funds in emerging biotech companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by FMR LLC may instill confidence and potentially attract other investors, positively impacting shareholder sentiment and potentially share price.
• Employees, Customers, Suppliers, Creditors: This filing is unlikely to have a direct or immediate impact on these stakeholders as it pertains solely to ownership structure, not operational or financial performance.

Key Dates

Recommendation

While the significant stake by FMR LLC is a positive signal, this Schedule 13G filing is purely an ownership disclosure and does not provide operational or financial performance data for Zenas Biopharma Inc. A 'hold' recommendation is appropriate as it acknowledges the positive institutional interest without making a definitive judgment on the company's fundamentals, which would require further analysis of its financial reports and strategic developments.

Keywords

Zenas Biopharma, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biopharma, Fidelity